As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

SBIR Banner

You are here

Phase IIB Bridge Award

FY2018 Phase IIB Bridge Award - All Agencies Now Eligible

The application for FY2018 Phase IIB Bridge Award is now closed. Please check back later for update. 

View the Funding Opportunity Announcement (FOA) for Phase IIB Bridge Award: RFA-CA-17-024

Both SBIR and STTR Phase II awardees from other Federal agencies are welcome to apply. Check Section III of the FOA for detailed eligibility criteria.


About the NCI SBIR Phase IIB Bridge Award

Hear more about the Phase IIB Bridge Award from NCI SBIR Program Director & Team Leader, Dr. Andy Kurtz

The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program has developed an innovative funding opportunity called the SBIR Phase IIB Bridge Award to support the next stage of development for Federally funded SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, diagnostics, and prognostics. The purpose of this award is to address the funding gap known as the "Valley of Death" between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a product or service toward commercialization. To achieve this goal, the Bridge Award funding opportunity is specifically designed to incentivize partnerships between Federally-funded SBIR Phase II awardees and third-party investors and/or strategic partners.

Budgets up to $1 million in total costs per year and project periods up to three years (a total of $3 million over three years) may be requested from NCI. Development efforts must address one of the following technical/scientific areas:

  1. Cancer Therapeutics;
  2. Cancer Imaging Technologies, Interventional Devices, and In Vivo Diagnostics; and/or
  3. In Vitro and Ex Vivo Cancer Diagnostics and Prognostics.

NCI intends to commit $10M for up to 10 new awards in FY2017.

Competitive preference and funding priority is given to applications deemed likely to result in a commercial product, as indicated by the applicant's ability to secure substantial independent third-party investor funds (i.e. at least $750,000 in total third-party investor funds over the entire project period). Examples of third-party investors include, but are not limited to, another company, a venture capital firm, an angel investor, a foundation, a university, or a research institution. Applicants must provide a commercialization plan that describes the long-term commercialization strategy and details on any independent third-party investor funding that has already been secured or will be provided during the Bridge Award project period.

Eligibility Requirements

An SBIR Phase IIB Bridge Award application must represent a continuation of the R&D efforts performed under a previous Federally-funded SBIR or STTR Phase II award nearing completion or recently ended.

  • Applications may be predicated on a previously funded SBIR Phase II grant or contract award.*
  • To be eligible under the current FOA, current Phase II projects MUST end on or before March 31, 2018.
  • In general, applications should be predicated on SBIR/STTR Phase II awards that ended not more than 24 months prior to the application receipt date, although the NCI will consider longer periods of hiatus on a case-by-case basis.
  • To be responsive to this FOA, the development activities completed under the previous SBIR or STTR Phase II award MUST provide the appropriate technical foundation to justify continued development of the technology for a cancer-relevant indication/use.  Platform technologies that were initially developed for a non-cancer indication/use (e.g., SBIR or STTR Phase II projects funded by an NIH Institute/Center other than the NCI, or SBIR or STTR Phase II projects funded by a Federal agency other than the NIH) may be responsive only if the earlier data demonstrate technical proof-of-concept that is scientifically relevant to the cancer indication/use.
  • The Phase II project period must end before a Phase IIB Bridge Award can be issued.

*NOTE: Applicants who intend to submit a Phase IIB Bridge Award application that is predicated on a Phase II award funded by a federal agency other than the NIH or a previous Phase II contract award MUST contact the SBIR Development Center prior to submission, so that the NCI can properly arrange for such applications to be accepted.


Current SBIR Phase IIB Bridge Awardees

See the NCI SBIR Bridge Award Success Stories to learn about all current Bridge Awardees and the cancer technologies they are developing.


Updated: May 12, 2017